• About
  • Advertise
  • Privacy & Policy
  • Contact
HK Businesswire
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
  • Home
  • News
    • All
    • Business
    • Politics
    • PR Newswire
    • Science
    • World
    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

    Federation secures prestigious Victorian International Education Award wins

    Federation secures prestigious Victorian International Education Award wins

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    TenPay Global and Mastercard collaborate to enable fast and secure remittances to Weixin Pay

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Dulwich College Ranjit Murugason Sustainability Fund Secures Renewed Support from LGT Bank Singapore to Advance Student-Led Initiatives

    Trending Tags

    • Trump Inauguration
    • United Stated
    • White House
    • Market Stories
    • Election Results
  • PR Newswire
  • Business
  • World
  • Entertainment
  • Sports
  • Tech
    • All
    • Apps
    • Gadget
    • Mobile
    • Startup

    Meituan Reports Q3 2025 Results: Revenue Reaches RMB95.5 Billion as Annual Transacting Users Surpass 800 Million

    Xiaomi Founder Lei Jun Boosts Stake as Company Ramps Up Buybacks, Signaling Confidence

    Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

    Xiaomi Produces 500,000th EV in Record Time, CEO Lei Jun Pledges Focus on Safety and Delivery

    Morrison Foerster Report: ESG Committees and Climate Policy Gaining Traction Among Asia’s Largest GPs

    Xiaomi’s Double 11 GMV Surges Past RMB 29 Billion as It Claims Top Domestic Phone Sales for Third Year

    Trending Tags

    • Nintendo Switch
    • CES 2017
    • Playstation 4 Pro
    • Mark Zuckerberg
  • Feature
No Result
View All Result
HK Businesswire
No Result
View All Result
Home News PR Newswire

Vantage Markets Partners with The Sapphire Project to Support Ocean Conservation in Australia

PR Newswire by PR Newswire
16 April 2025
in PR Newswire
0
Vantage Markets Partners with The Sapphire Project to Support Ocean Conservation in Australia
0
SHARES
2
VIEWS
Share on FacebookShare on Twitter

SYDNEY, April 16, 2025 /PRNewswire/ — Vantage Markets is proud to announce its partnership with The Sapphire Project, an esteemed Australian-founded initiative dedicated to ocean conservation and marine ecosystem restoration. This collaboration marks a significant step in Vantage‘s ongoing Environmental, Social, and Governance (ESG) efforts, aligning its commitment to sustainability, innovation, and global impact.

Vantage Markets Partners with The Sapphire Project to Support Ocean Conservation in Australia
Vantage Markets Partners with The Sapphire Project to Support Ocean Conservation in Australia

As a global leader in CFD multi-products trading, Vantage is deeply invested in fostering a sustainable future. The ocean is a vital part of the global ecosystem, and protecting marine biodiversity is crucial for climate stability and environmental balance. Through this partnership, Vantage joins The Sapphire Project‘s mission to drive awareness and support critical conservation initiatives that preserve Australia‘s marine ecosystems and inspire global impact.

Jack Kelly, Head of Sales, Vantage Australia, shared his excitement about the partnership: “At Vantage, we believe that true success goes beyond financial markets—it‘s about making a lasting impact on the world around us. Partnering with The Sapphire Project allows us to support meaningful ocean conservation efforts right here in Australia. Just as we provide traders with the tools to navigate global markets, we are equally committed to safeguarding our oceans for future generations.”

The Sapphire Project unites business leaders, innovators, and sustainability advocates in a shared effort to protect marine life and promote environmental sustainability.

Founded in 2021, it has raised over $4 million for high-impact ocean conservation and continues to expand globally through curated experiences and collaborations. As a key partner, Vantage will contribute to awareness campaigns, community-driven projects, and conservation initiatives that drive real change.

By leveraging its platform and influence, Vantage aims to inspire clients, partners, and the wider financial industry to act toward ocean conservation and sustainable development.

Vantage is recognised as a premium trading brand, providing clients with a trading experience that combines advanced technology, expert market insights, and lightning-fast execution. This partnership reaffirms that luxury and responsibility can coexist, allowing clients to trade while contributing to a greater cause.

With this partnership, Vantage strengthens its ESG initiatives, reinforcing the belief that success in the financial world should go hand in hand with sustainability and social responsibility. Through The Sapphire Project, Vantage hopes to inspire more businesses and individuals to take part in collective environmental preservation efforts.

To learn more about Vantage‘s CSR initiatives and The Sapphire Project, visit Vantage Markets.

About Vantage

Vantage Markets (or Vantage) is a multi-asset broker offering clients access to a nimble and powerful service for trading Forex and Contracts for Difference (CFDs) products on, Commodities, Indices, Shares, ETFs, and Bonds.

With over 15 years of market experience, Vantage transcends the role of broker, providing a trusted trading ecosystem, an award-winning mobile trading app, and a user-friendly trading platform that empowers clients to seize trading opportunities. Download the Vantage App on App Store or Google Play.

trade smarter @vantage

Vantage Global Prime Pty Ltd (ACN 157 768 566), located at 12/15 Castlereagh Street, Sydney, NSW, Australia, 2000, and is authorised and regulated by the Australian Securities & Investments Commission (ASIC) AFSL no. 428901.

Trading derivatives carries significant risks. It is not suitable for all investors and if you are a professional client, you could lose substantially more than your initial investment. When acquiring our derivative products, you have no entitlement, right or obligation to the underlying financial assets. Past performance is no indication of future performance and tax laws are subject to change. The information on this website is general in nature and doesn’t take into account your personal objectives, financial circumstances, or needs. Accordingly, before acting on the advice, you should consider whether the advice is suitable for you having regard to your objectives, financial situation and needs. We encourage you to seek independent advice if necessary.

You should consider whether you’re part of our target market by reviewing our Target Market Determination (TMD), reading our Product Disclosure Statement (PDS), and other legal documents to ensure you fully understand the risks before you make any trading decisions. We encourage you to seek independent advice if necessary.

The Sapphire Project does not receive any funds from ticket sales or donations.
The Great Barrier Reef Foundation (ABN 82 090 616 443) is partnered with The Sapphire Project to administer and distribute raised funds including ticket sales, donations and charity proceeds to the recipient ocean organisations as nominated by the Sapphire committee with no administration fee, and independently checked. All supported organisations are registered charities (DGR1) in Australia and are eligible to receive tax-deductible donations. The foundation will provide tax-deductible receipts for all donations for Australian tax purposes. Donations of $2.00 or more are tax deductible in Australia.  Thanks to our generous sponsors who are making our work possible, ensuring that 100% of every ticket sold and every dollar raised go directly into impactful ocean conservation.

Tags: prnewswire
PR Newswire

PR Newswire

PR Newswire is the industry’s leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world.

Read More

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
  • Trending
  • Comments
  • Latest
Tai Po fire death toll climbs to 44, 56 injured

Tai Po fire death toll climbs to 44, 56 injured

26 November 2025
No for now on women deacons, Vatican commission says

No for now on women deacons, Vatican commission says

4 December 2025

Ant Group’s Multimodal AI Assistant LingGuang Surpasses 1 Million Downloads in Four Days

23 November 2025
Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

Hang Seng Indexes Company and Cyberport Partner to Drive Gen-AI Adoption in Index Calculation

4 November 2025
ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025

Recent News

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma

8 December 2025
Federation secures prestigious Victorian International Education Award wins

Federation secures prestigious Victorian International Education Award wins

8 December 2025
Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

Investment of Approx. USD 460,000 for the Development of a Prototype Mpox Detection Test with NIPRO, TBA, Japan Institute for Health Security and others

8 December 2025
RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

8 December 2025
HK Businesswire

Stay ahead with the latest insights on Hong Kong’s economy, finance, and investments. From market trends to policy updates, we bring you in-depth analysis and expert opinions.

📩 Subscribe to our newsletter for exclusive updates.
📍 Follow us on social media for real-time news.
📧 Contact us: info@hongkong-invest.com

Follow Us

  • About
  • Advertise
  • Privacy & Policy
  • Contact

© 2025 by HKBusinesswire.com

No Result
View All Result

© 2025 by HKBusinesswire.com